ATE489091T1 - Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen - Google Patents

Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen

Info

Publication number
ATE489091T1
ATE489091T1 AT07765584T AT07765584T ATE489091T1 AT E489091 T1 ATE489091 T1 AT E489091T1 AT 07765584 T AT07765584 T AT 07765584T AT 07765584 T AT07765584 T AT 07765584T AT E489091 T1 ATE489091 T1 AT E489091T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
cardiovascular diseases
dha esters
dha
Prior art date
Application number
AT07765584T
Other languages
English (en)
Inventor
Frederique Brune
Andre Delhon
Jean Gardette
Jean Francois Patoiseau
Alain Marty
Etienne Severac
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE489091(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of ATE489091T1 publication Critical patent/ATE489091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT07765584T 2006-06-23 2007-06-22 Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen ATE489091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in treatment and prevention of cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE489091T1 true ATE489091T1 (de) 2010-12-15

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07765584T ATE489091T1 (de) 2006-06-23 2007-06-22 Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen

Country Status (38)

Country Link
US (2) US8034377B2 (de)
EP (1) EP2034999B9 (de)
JP (1) JP5053372B2 (de)
KR (1) KR101380128B1 (de)
CN (1) CN101472590A (de)
AR (1) AR061622A1 (de)
AT (1) ATE489091T1 (de)
AU (1) AU2007262958B2 (de)
BR (1) BRPI0713725A2 (de)
CA (1) CA2655570C (de)
CL (1) CL2010001123A1 (de)
CO (1) CO6150156A2 (de)
CR (1) CR10507A (de)
DE (1) DE602007010776D1 (de)
DK (1) DK2034999T3 (de)
EC (1) ECSP099039A (de)
ES (1) ES2355611T3 (de)
FR (1) FR2902659A1 (de)
GE (1) GEP20125464B (de)
HN (1) HN2008001771A (de)
HR (1) HRP20110086T1 (de)
IL (1) IL195562A (de)
MA (1) MA30584B1 (de)
MX (1) MX2009000103A (de)
MY (1) MY145985A (de)
NO (1) NO20090334L (de)
NZ (1) NZ573454A (de)
PL (1) PL2034999T3 (de)
PT (1) PT2034999E (de)
RS (1) RS51629B (de)
RU (1) RU2451672C2 (de)
SA (1) SA07280345B1 (de)
SI (1) SI2034999T1 (de)
TN (1) TNSN08527A1 (de)
TW (1) TWI389888B (de)
UA (1) UA96156C2 (de)
WO (1) WO2007147899A2 (de)
ZA (1) ZA200900334B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
EP2582391B1 (de) * 2010-06-18 2018-10-03 XBiotech, Inc Arthritis-behandlung
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
EP3582813A4 (de) 2017-02-16 2020-12-30 XBiotech, Inc Behandlung von hidradenitis suppurativa
WO2018152509A1 (en) * 2017-02-20 2018-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (de) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
JPS59502024A (ja) 1982-11-16 1984-12-06 イレナ　モッチャン　マルス リュウマチ性疾病治療剤
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
DK0823897T3 (da) 1995-05-01 2004-12-06 Scarista Ltd Nicotinsyreestere og farmaceutiske præparater indeholdende disse
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
DK1157692T3 (da) 2000-05-22 2006-02-06 Pro Aparts Investimentos E Con Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1466597A1 (de) * 2003-04-07 2004-10-13 Clinigenetics Verwendung von dha-Esteren in der Behandlung kardiovasculärer Krankheiten
RU2005135565A (ru) 2003-04-17 2006-07-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Поливитаминная и минеральная добавка для беременных женщин

Also Published As

Publication number Publication date
NO20090334L (no) 2009-03-04
RU2451672C2 (ru) 2012-05-27
ZA200900334B (en) 2009-12-30
WO2007147899A3 (en) 2008-03-13
US8227479B2 (en) 2012-07-24
EP2034999B9 (de) 2011-03-09
MA30584B1 (fr) 2009-07-01
SI2034999T1 (sl) 2011-02-28
FR2902659A1 (fr) 2007-12-28
NZ573454A (en) 2010-10-29
WO2007147899B1 (en) 2008-05-02
IL195562A (en) 2012-06-28
TNSN08527A1 (en) 2010-04-14
PT2034999E (pt) 2011-01-19
HN2008001771A (es) 2011-01-24
MX2009000103A (es) 2009-01-23
PL2034999T3 (pl) 2011-05-31
EP2034999B1 (de) 2010-11-24
KR20090024794A (ko) 2009-03-09
CR10507A (es) 2009-02-05
DK2034999T3 (da) 2011-01-24
RS51629B (sr) 2011-08-31
CA2655570C (en) 2015-09-08
JP2009544576A (ja) 2009-12-17
AU2007262958A1 (en) 2007-12-27
SA07280345B1 (ar) 2011-01-15
US20090312354A1 (en) 2009-12-17
DE602007010776D1 (de) 2011-01-05
IL195562A0 (en) 2009-09-01
JP5053372B2 (ja) 2012-10-17
CA2655570A1 (en) 2007-12-27
CO6150156A2 (es) 2010-04-20
UA96156C2 (ru) 2011-10-10
TW200811108A (en) 2008-03-01
ECSP099039A (es) 2009-02-27
TWI389888B (zh) 2013-03-21
BRPI0713725A2 (pt) 2012-10-30
WO2007147899A2 (en) 2007-12-27
MY145985A (en) 2012-05-31
AR061622A1 (es) 2008-09-10
RU2008152248A (ru) 2010-07-27
GEP20125464B (en) 2012-04-10
ES2355611T3 (es) 2011-03-29
EP2034999A2 (de) 2009-03-18
AU2007262958B2 (en) 2011-10-27
US8034377B2 (en) 2011-10-11
HRP20110086T1 (hr) 2011-03-31
CN101472590A (zh) 2009-07-01
KR101380128B1 (ko) 2014-04-11
US20110237613A1 (en) 2011-09-29
CL2010001123A1 (es) 2011-03-25

Similar Documents

Publication Publication Date Title
ATE489091T1 (de) Dha-ester und ihre verwendung bei der behandlung und der prävention von kardiovaskulären erkrankungen
ATE448206T1 (de) Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
SI2084151T1 (sl) Substituirani dihidropirazoloni za zdravljenje kardiovaskularnih in hematoloških bolezni
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
EP2007385A4 (de) Kardiovaskuläre zusammensetzung und ihre verwendung zur behandlung von morbus alzheimer
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP2118300A4 (de) Verhinderung und behandlung synukleinopathischer und amyloidogener krankheiten
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
DE502005007427D1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1804761A4 (de) Zusammensetzungen und verfahren zur behandlung von hautverfärbungen
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
PL2297106T3 (pl) Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
EP1768689A4 (de) Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
DE602005015486D1 (de) Esterderivate von ascorbinsäure und 2-ketosäuresacchariden
EP2307034A4 (de) Extrakt von coptidis rhizoma und neue verwendung dafür bei der behandlung von atemwegserkrankungen
DK1919290T3 (da) Fremgangsmåder og produkter til behandling af sygdomme
DE602006010042D1 (de) Verwendung von nichtsteroidalen entzündungshemmern bei der behandlung von akuter und chronischer bronchitis
ATE479716T1 (de) Copolymerisate und ihre verwendung zur behandlung von flexiblen substraten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2034999

Country of ref document: EP